-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Nabriva Therapeutics plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q2 2023.
- Nabriva Therapeutics plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $98K, a 70.7% decline year-over-year.
- Nabriva Therapeutics plc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $1.73M.
- Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2022 was $1.97M, a 40.2% decline from 2021.
- Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2021 was $3.29M, a 36.9% decline from 2020.
- Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2020 was $5.22M, unchanged from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)